Equities Analysts Issue Forecasts for Insmed FY2026 Earnings

Insmed Incorporated (NASDAQ:INSM) – Leerink Partnrs reduced their FY2026 earnings per share (EPS) estimates for Insmed in a research note issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now expects that the biopharmaceutical company will earn ($3.39) per share for the year, down from their previous estimate of ($3.32). The consensus estimate for Insmed’s current full-year earnings is ($5.44) per share.

A number of other equities analysts have also weighed in on the company. Bank of America increased their price target on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. upped their price target on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research report on Friday, November 22nd. Finally, Truist Financial reiterated a “buy” rating and set a $105.00 price objective (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $83.67.

Insmed Price Performance

INSM opened at $76.75 on Wednesday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The business has a fifty day simple moving average of $71.19 and a 200-day simple moving average of $72.72. Insmed has a fifty-two week low of $21.92 and a fifty-two week high of $80.53.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The company had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. Insmed’s quarterly revenue was up 18.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.10) earnings per share.

Insider Buying and Selling at Insmed

In related news, insider Martina M.D. Flammer sold 1,384 shares of the firm’s stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $68.72, for a total value of $95,108.48. Following the transaction, the insider now directly owns 100,165 shares of the company’s stock, valued at approximately $6,883,338.80. This trade represents a 1.36 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO William Lewis sold 31,805 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $70.18, for a total value of $2,232,074.90. Following the sale, the chief executive officer now directly owns 379,534 shares of the company’s stock, valued at $26,635,696.12. The trade was a 7.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 104,740 shares of company stock worth $7,161,294 over the last ninety days. 4.60% of the stock is currently owned by insiders.

Institutional Trading of Insmed

A number of institutional investors and hedge funds have recently modified their holdings of INSM. V Square Quantitative Management LLC acquired a new stake in Insmed in the 3rd quarter valued at approximately $30,000. GAMMA Investing LLC boosted its position in shares of Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 224 shares during the period. Exchange Traded Concepts LLC grew its stake in shares of Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 627 shares during the last quarter. JCIC Asset Management Inc. bought a new position in Insmed during the third quarter worth $133,000. Finally, Quantbot Technologies LP acquired a new position in Insmed during the 3rd quarter valued at $133,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.